Schlaff W D, Dugoff L, Damewood M D, Rock J A
Department of Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore.
Obstet Gynecol. 1990 Apr;75(4):646-8.
Between 1977-1989, 29 women with symptomatic endometriosis were treated with megestrol acetate by the Johns Hopkins Division of Reproductive Endocrinology. All had previously received one or more alternative medical treatments for endometriosis, in each case discontinued because of poor response or development of unacceptable side effects. Treatment consisted of a daily dose of 40 mg megestrol acetate orally for up to 24 months. Disease-related symptoms (dysmenorrhea, noncyclic pelvic pain, and dyspareunia) were relieved in 86% of the subjects treated with an adequate course of therapy. Side effects were fairly well tolerated, although eight women discontinued treatment within 2 months and two others stopped the drug by 4 months. These preliminary findings suggest that megestrol acetate may be an effective treatment for patients with endometriosis, even those who have been unresponsive to other modes of therapy.
1977年至1989年间,约翰霍普金斯生殖内分泌科用醋酸甲地孕酮治疗了29例有症状的子宫内膜异位症女性。所有患者此前均接受过一种或多种针对子宫内膜异位症的替代药物治疗,但每种治疗均因疗效不佳或出现难以接受的副作用而停药。治疗方法为每日口服40毫克醋酸甲地孕酮,疗程最长24个月。在接受足够疗程治疗的受试者中,86%的与疾病相关的症状(痛经、非周期性盆腔疼痛和性交困难)得到缓解。副作用的耐受性相当好,不过有8名女性在2个月内停药,另外两名女性在4个月时停药。这些初步研究结果表明,醋酸甲地孕酮可能是子宫内膜异位症患者的一种有效治疗方法,即使是那些对其他治疗方式无反应的患者。